ADCs for HER2 + MBC

Key Content Areas Include:

Review clinical data in HER2 + MBC from ESMO 2021
Discuss optimal therapy selection based on individual patient characteristics in the HER2-positive metastatic breast cancer setting
Describe potential adverse events associated with current treatment options for HER2-positive metastatic breast cancer

Chair

Stephen K. Chia, MD, FRCP

Speakers

Shanu Modi, MD

This program has been made possible through unrestricted support from AstraZeneca.